In adults with membranous nephropathy, should urine albumin-to-creatinine ratio (uACR) be used instead of urine protein-to-creatinine ratio (uPCR) for monitoring disease activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

uACR versus uPCR for Monitoring Membranous Nephropathy

For monitoring membranous nephropathy, use uPCR (urine protein-to-creatinine ratio) rather than uACR (urine albumin-to-creatinine ratio). While uACR is preferred for diabetic kidney disease, membranous nephropathy requires measurement of total proteinuria, not just albumin.

Why uPCR is Superior for Membranous Nephropathy

The key distinction lies in the pathophysiology of membranous nephropathy versus diabetic kidney disease:

  • Membranous nephropathy causes nephrotic-range proteinuria that includes substantial non-albumin proteins (immunoglobulins, other plasma proteins) 1
  • uACR only measures albumin, missing significant portions of the total protein loss that are clinically and prognostically important
  • uPCR captures total protein excretion, which is what drives the nephrotic syndrome complications (edema, thrombosis, infection risk) and reflects true disease activity

Evidence Supporting uPCR in Glomerular Disease

The KDIGO 2021 glomerular disease guidelines explicitly recommend 24-hour urine collection for total protein excretion when initiating or intensifying immunosuppression in glomerular diseases 1. While spot uPCR can be used for trending in individual patients over time, the guideline emphasizes that total protein quantification is essential for treatment decisions in glomerulonephritis.

Research directly comparing these measures in membranous nephropathy shows that spot urine PCR does not reliably correlate with 24-hour proteinuria in nephrotic syndrome (r=0.289, P=0.17), unlike in IgA nephropathy where correlation is strong 2. This poor correlation in nephrotic-range proteinuria makes uPCR less reliable but still superior to uACR, which misses non-albumin proteins entirely.

Practical Monitoring Algorithm

For initial diagnosis and treatment decisions:

  • Obtain 24-hour urine collection for total protein excretion 1, 3
  • This is the gold standard when deciding to start immunosuppression

For ongoing monitoring:

  • Use spot uPCR collected at the same time of day (preferably first morning void) 1
  • Track trends within the individual patient rather than comparing absolute values
  • Confirm significant changes with 24-hour collection if considering treatment modifications
  • A doubling of uPCR exceeds laboratory variability and warrants evaluation 4

Treatment response criteria in membranous nephropathy:

  • Complete remission: uPCR <0.5 g/g (or <500 mg/g) 5
  • Partial remission: >50% reduction in proteinuria
  • These thresholds are based on total protein, not albumin alone

Why uACR Guidelines Don't Apply Here

The extensive guideline evidence favoring uACR 6, 7, 8 specifically addresses diabetic kidney disease, hypertension, and early CKD screening—conditions where albumin is the predominant and earliest protein lost. The 2023 Diabetes Care guidelines and 2024 KDIGO CKD guidelines appropriately recommend uACR for these populations because:

  • Albuminuria precedes total proteinuria in diabetic nephropathy
  • Lower levels of albumin (30-300 mg/g) predict cardiovascular and kidney outcomes
  • These patients rarely have nephrotic-range proteinuria

However, a recent 2025 meta-analysis found that uACR was more strongly associated with kidney failure than uPCR (HR 2.55 vs 2.40 per SD increment) across diverse CKD populations 9. This might suggest uACR superiority in general CKD, but this study's population was predominantly diabetic and non-nephrotic, making it less applicable to membranous nephropathy specifically.

Critical Caveats

When uACR is high (>500-1000 mg/g), consider switching to uPCR 6. At nephrotic levels, albumin assays may have technical issues and non-albumin proteins become proportionally more significant.

Do not rely on a single measurement for treatment decisions. The NKF guidelines recommend confirming persistent proteinuria with two or more positive results temporally spaced over 3 months 6.

Beware of collection errors: Both spot ratios and 24-hour collections have limitations. Spot samples vary with hydration, activity, and time of day. 24-hour collections are frequently incomplete. When using spot uPCR for trending, maintain consistency in collection timing 1.

References

Related Questions

Why does urinary albumin decrease while the albumin‑creatinine ratio remains unchanged?
What is the difference between the urinary albumin-to-creatinine ratio (UACR) and a 24‑hour urine collection?
What does a rise in random urine albumin-to-creatinine ratio from 134 mg/g to 298 mg/g over one month indicate, and what are the recommended next steps for management?
What is the significance of a urine albumin-to-creatinine ratio of 98 mg/g and what are the recommended management steps?
How should an elevated urinary albumin-to-creatinine ratio with a negative urine dipstick for protein be evaluated and managed?
What is the recommended management for moderate knee joint effusion associated with osteoarthritis?
Which MRI sequences and views should be ordered for a contrast‑enhanced study of the spine (and brain if not already performed)?
What pre‑hospital interventions are recommended for a patient who has fallen?
In a patient with ulcerative lesions on the lower lip that show light growth of Pseudomonas aeruginosa, is this organism likely normal flora or an infection, and what is the appropriate treatment?
What is the medical justification for initiating buprenorphine‑naloxone (Suboxone) therapy in a patient who uses illicit opioids (approximately 1 g of heroin or fentanyl‑containing product every other day)?
I developed sudden heel pain and cannot bear weight after standing up from sitting; what immediate steps and evaluation should I take?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.